Please login to the form below
Intra-Cellular Therapeutics
This page shows the latest Intra-Cellular Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Intra-Cellular soars on FDA approval of schizophrenia drug
Shares rocketed following the announcement. US biotech Intra-Cellular Therapeutics has scored approval for its antipsychotic drug Caplyta for the treatment of schizophrenia, to the delight of investors. ... The approval is an early Christmas present for
Latest news
-
Intra-Cellular plans schizophrenia filing in 2018
Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Intra-Cellular maintains this
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Former NICE chair Sir Michael Rawlins to lead MHRA
More recently Sir Michael has served on the board of US-based biotech Intra-Cellular Therapeutics.
-
Former NICE chair joins board of biotech
Sir Michael Rawlins joins board of Intra-Cellular Therapeutics. The former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US ... His expertise in the cost-effectiveness of new
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- The patient voice – the value of patient-reported outcomes in HTA
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- ONS data reveals significant decrease in COVID-19 antibodies
- Researchers create ‘world’s largest’ database for predicting cancer treatment response
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- ONS data reveals significant decrease in COVID-19 antibodies
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
PMHub
Research Partnership
Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
